Illumina's Jay Flatley tells the story of his 2011 meeting with Roche in a video from Biocom's Speaker Series posted by the San Diego Union-Tribune.

In 2011, Illumina's stock price fell from the $70-a-share to $60-a-share range to about $24 a share, and that, Flatley says, was the impetus for Roche to come calling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.